Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination

Exclusion Criteria

• •Significant clinical illness within the 2 weeks preceding the first dose of investigational products, as judged by the Investigator
• •History of mental, cardiac, renal, hepatitis, neurological, or significant gastrointestinal disease, as judged by the Investigator
• •Condition which could modify the absorption of the investigational products, as judged by the Investigator